On Friday, Shares of Wells Fargo & Co (NYSE:WFC), dropped -0.33% to $56.72.
Wells Fargo & Company, unveiled redesigned treasury administration applications, counting information reporting and fraud prevention, on its Commercial Electronic Office portal. The enhancements speed up business customers’ access to their information and ability to get things done on any mobile device they choose, counting smartphones, tablets, or laptops.
The declarement coincided with the 15-year anniversary this month of the CEO portal, the banking industry’s first single sign-on point of access to a variety of financial services for businesses in 2000. Recently, Wells Fargo commercial, corporate, and institutional customers in more than 190 countries use the CEO portal to connect to 90-plus online banking services. Active CEO users have raised 120 percent in the last five years.
Wells Fargo & Company provides retail, commercial, and corporate banking services to individuals, businesses, and institutions. Its Community Banking segment offers checking, savings, market rate, individual retirement, and health savings accounts, in addition to time deposits and remittances; and lines of credit, auto floor plan lines, equity lines and loans, equipment and transportation loans, education and residential mortgage loans, and debit and credit cards.
Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), climbed 1.00% to $61.56.
Teva Pharmaceutical Industries Ltd, stated top line results from the double-blind, placebo-controlled Phase 2b study designed to evaluate the safety and efficacy of topically applied TV-45070 (4% and 8% w/w ointment) in patients with chronic pain due to osteoarthritis (OA) of the knee.
TV-45070 is a small molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, counting those that are expressed in the pain-sensing peripheral nervous system. Results from this trial showed that TV-45070 4% and 8% did not demonstrate statistically noteworthy difference from placebo in efficacy endpoints of reductions in pain due to OA.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines.
Finally, Alder Biopharmaceuticals Inc (NASDAQ:ALDR), gained 1.61% $ 51.75.
Alder Biopharmaceuticals Inc, declared that the underwriters of its formerly declared public offering of common stock have exercised in full their option to purchase an additional 674,157 shares of common stock. The closing of the sale of all shares occurred. Gross proceeds from the offering of an aggregate of 5,168,539 shares at a public offering price of $44.50 per share, before underwriting discounts and commissions and offering expenses, were about $230 million.
Credit Suisse, Leerink Partners and Wells Fargo Securities acted as joint book-running managers for the offering. Bernstein acted as co-manager for the offering.
Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes various therapeutic antibodies in the United States and Australia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
